![Chad D. Galderisi](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Active connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Sheridan G. Snyder | M | - |
MolecularMD Corp.
![]() MolecularMD Corp. Medical/Nursing ServicesHealth Services MolecularMD Corp. develops and commercializes molecular diagnostics for oncology applications. Its tests are designed to assist pharmaceutical companies with selection, monitoring and management of patients treated with molecularly-targeted cancer therapies. The firm integrates gold-standard and innovative platform technologies with custom clinical assay design and validation to accelerate all phases of clinical development, including FDA approval and commercialization of in vitro companion diagnostic tests for novel anticancer agents. The company was founded by Brian Druker, Sheridan G. Snyder, and Chad D. Galderisi in 2005 and is headquartered in Portland, OR. | 19 years |
Drew Graham | M | - |
MolecularMD Corp.
![]() MolecularMD Corp. Medical/Nursing ServicesHealth Services MolecularMD Corp. develops and commercializes molecular diagnostics for oncology applications. Its tests are designed to assist pharmaceutical companies with selection, monitoring and management of patients treated with molecularly-targeted cancer therapies. The firm integrates gold-standard and innovative platform technologies with custom clinical assay design and validation to accelerate all phases of clinical development, including FDA approval and commercialization of in vitro companion diagnostic tests for novel anticancer agents. The company was founded by Brian Druker, Sheridan G. Snyder, and Chad D. Galderisi in 2005 and is headquartered in Portland, OR. | - |
Matt Rice | M | - |
MolecularMD Corp.
![]() MolecularMD Corp. Medical/Nursing ServicesHealth Services MolecularMD Corp. develops and commercializes molecular diagnostics for oncology applications. Its tests are designed to assist pharmaceutical companies with selection, monitoring and management of patients treated with molecularly-targeted cancer therapies. The firm integrates gold-standard and innovative platform technologies with custom clinical assay design and validation to accelerate all phases of clinical development, including FDA approval and commercialization of in vitro companion diagnostic tests for novel anticancer agents. The company was founded by Brian Druker, Sheridan G. Snyder, and Chad D. Galderisi in 2005 and is headquartered in Portland, OR. | - |
Connections Chart
Multi-company connection
Former connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Dan Snyder | M | - |
MolecularMD Corp.
![]() MolecularMD Corp. Medical/Nursing ServicesHealth Services MolecularMD Corp. develops and commercializes molecular diagnostics for oncology applications. Its tests are designed to assist pharmaceutical companies with selection, monitoring and management of patients treated with molecularly-targeted cancer therapies. The firm integrates gold-standard and innovative platform technologies with custom clinical assay design and validation to accelerate all phases of clinical development, including FDA approval and commercialization of in vitro companion diagnostic tests for novel anticancer agents. The company was founded by Brian Druker, Sheridan G. Snyder, and Chad D. Galderisi in 2005 and is headquartered in Portland, OR. | - |
Stephane Wong | M | - |
MolecularMD Corp.
![]() MolecularMD Corp. Medical/Nursing ServicesHealth Services MolecularMD Corp. develops and commercializes molecular diagnostics for oncology applications. Its tests are designed to assist pharmaceutical companies with selection, monitoring and management of patients treated with molecularly-targeted cancer therapies. The firm integrates gold-standard and innovative platform technologies with custom clinical assay design and validation to accelerate all phases of clinical development, including FDA approval and commercialization of in vitro companion diagnostic tests for novel anticancer agents. The company was founded by Brian Druker, Sheridan G. Snyder, and Chad D. Galderisi in 2005 and is headquartered in Portland, OR. | - |
Ryan Dunlap | M | 54 |
MolecularMD Corp.
![]() MolecularMD Corp. Medical/Nursing ServicesHealth Services MolecularMD Corp. develops and commercializes molecular diagnostics for oncology applications. Its tests are designed to assist pharmaceutical companies with selection, monitoring and management of patients treated with molecularly-targeted cancer therapies. The firm integrates gold-standard and innovative platform technologies with custom clinical assay design and validation to accelerate all phases of clinical development, including FDA approval and commercialization of in vitro companion diagnostic tests for novel anticancer agents. The company was founded by Brian Druker, Sheridan G. Snyder, and Chad D. Galderisi in 2005 and is headquartered in Portland, OR. | - |
Frederick L. Eibel | M | 60 |
MolecularMD Corp.
![]() MolecularMD Corp. Medical/Nursing ServicesHealth Services MolecularMD Corp. develops and commercializes molecular diagnostics for oncology applications. Its tests are designed to assist pharmaceutical companies with selection, monitoring and management of patients treated with molecularly-targeted cancer therapies. The firm integrates gold-standard and innovative platform technologies with custom clinical assay design and validation to accelerate all phases of clinical development, including FDA approval and commercialization of in vitro companion diagnostic tests for novel anticancer agents. The company was founded by Brian Druker, Sheridan G. Snyder, and Chad D. Galderisi in 2005 and is headquartered in Portland, OR. | - |
Brian Druker | M | 68 |
MolecularMD Corp.
![]() MolecularMD Corp. Medical/Nursing ServicesHealth Services MolecularMD Corp. develops and commercializes molecular diagnostics for oncology applications. Its tests are designed to assist pharmaceutical companies with selection, monitoring and management of patients treated with molecularly-targeted cancer therapies. The firm integrates gold-standard and innovative platform technologies with custom clinical assay design and validation to accelerate all phases of clinical development, including FDA approval and commercialization of in vitro companion diagnostic tests for novel anticancer agents. The company was founded by Brian Druker, Sheridan G. Snyder, and Chad D. Galderisi in 2005 and is headquartered in Portland, OR. | - |
Courtney Fuller | F | - |
MolecularMD Corp.
![]() MolecularMD Corp. Medical/Nursing ServicesHealth Services MolecularMD Corp. develops and commercializes molecular diagnostics for oncology applications. Its tests are designed to assist pharmaceutical companies with selection, monitoring and management of patients treated with molecularly-targeted cancer therapies. The firm integrates gold-standard and innovative platform technologies with custom clinical assay design and validation to accelerate all phases of clinical development, including FDA approval and commercialization of in vitro companion diagnostic tests for novel anticancer agents. The company was founded by Brian Druker, Sheridan G. Snyder, and Chad D. Galderisi in 2005 and is headquartered in Portland, OR. | - |
Glenn J. Dozier | M | 74 |
MolecularMD Corp.
![]() MolecularMD Corp. Medical/Nursing ServicesHealth Services MolecularMD Corp. develops and commercializes molecular diagnostics for oncology applications. Its tests are designed to assist pharmaceutical companies with selection, monitoring and management of patients treated with molecularly-targeted cancer therapies. The firm integrates gold-standard and innovative platform technologies with custom clinical assay design and validation to accelerate all phases of clinical development, including FDA approval and commercialization of in vitro companion diagnostic tests for novel anticancer agents. The company was founded by Brian Druker, Sheridan G. Snyder, and Chad D. Galderisi in 2005 and is headquartered in Portland, OR. | - |
Glenn A. Miller | M | - |
MolecularMD Corp.
![]() MolecularMD Corp. Medical/Nursing ServicesHealth Services MolecularMD Corp. develops and commercializes molecular diagnostics for oncology applications. Its tests are designed to assist pharmaceutical companies with selection, monitoring and management of patients treated with molecularly-targeted cancer therapies. The firm integrates gold-standard and innovative platform technologies with custom clinical assay design and validation to accelerate all phases of clinical development, including FDA approval and commercialization of in vitro companion diagnostic tests for novel anticancer agents. The company was founded by Brian Druker, Sheridan G. Snyder, and Chad D. Galderisi in 2005 and is headquartered in Portland, OR. | - |
Peter Maag | M | 57 |
MolecularMD Corp.
![]() MolecularMD Corp. Medical/Nursing ServicesHealth Services MolecularMD Corp. develops and commercializes molecular diagnostics for oncology applications. Its tests are designed to assist pharmaceutical companies with selection, monitoring and management of patients treated with molecularly-targeted cancer therapies. The firm integrates gold-standard and innovative platform technologies with custom clinical assay design and validation to accelerate all phases of clinical development, including FDA approval and commercialization of in vitro companion diagnostic tests for novel anticancer agents. The company was founded by Brian Druker, Sheridan G. Snyder, and Chad D. Galderisi in 2005 and is headquartered in Portland, OR. | 8 years |
Statistics
Country | Connections | % of total |
---|---|---|
United States | 12 | 100.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Chad D. Galderisi
- Personal Network